Moreover, KRT14 expression has been implicated in MHC class II presentation in breast cancer [35], suggesting that down-regulation of KRT14 in TNBC could result in increased MHC II expression and facilitate the activation of CD4+ T cells. This evidence concerns the gene CD4 and breast carcinoma.